Skip to Main Content

Paper Details

Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
Oncoimmunology
18
2021
Adrenocortical carcinoma, CA209-538, PD-1, PD-L1, Participants, adrenocortical carcinoma, advanced adrenocortical carcinoma, advanced rare cancers, anti-CTLA-4, anti-CTLA-4 antibody, anti-PD-1, anti-PD-1 antibody, hepatitis, ipilimumab, malignancy, patient, patients, tumors
Author NameAffiliation
Bo GaoBlacktown Hospital and the University of Sydney
Damien Kee
Damien KeePeter MacCallum Cancer Centre
Jonathan Cebon
Jonathan CebonOlivia Newton-John Cancer Research Institute
Jonathan CebonLa Trobe University
  • 1 - 6

Datasets

Release 1.2